2BBBullish & Bearish
Arrowhead Pharmaceuticals, Inc. (ARWR) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 40 out of 100.
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act through RNA interference mechanisms of action. The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular disease.
Arrowhead Pharmaceuticals, Inc.’s current 2BB score is 40 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 68 | High |
| Momentum | 51 | Stable |
| Financial strength | 20 | Weak |
| Quality | 100 | Very Strong |
| Risk | 40 | Moderate |
| CEO | Christopher Richard Anzalone |
| Headquarters | Pasadena, California, United States |
| Founded | Jan 1, 2004 |
| Employees | 711 |
| 52-week range | $21.61 – $95.49 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-03 | — | -1.3413 | — | $44.34M |
| 2026-11-23 | — | -1.7283 | — | $56.96M |
| 2026-08-04 | — | -1.3464 | — | $55.38M |
| 2026-05-07 | -0.93 | -1.211 | $73.74M | $81.59M |